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Nonalcoholic fatty liver disease (NAFLD) is a common 
chronic liver disease whose prevalence has reached global 
epidemic proportions, both in adults and children (1). 
There is consistent clinical and epidemiological evidence 
supporting the assertion that NAFLD may progress 
from a benign histological stage characterized by hepatic 
triglyceride accumulation, also known as simple steatosis, to 
a more severe histological picture characterized by liver cell 
injury, a mixed inflammatory lobular infiltrate, and variable 
fibrosis named nonalcoholic steatohepatitis (NASH) (1). 
Numerous factors influence the disease severity and 
progression, including genetic predisposition (2) and 
aberrant tissue-specific DNA methylation modifications 
that have been observed not only in the nuclear (1,3,4) 
but the mitochondrial genome as well (5). Presently, 
DNA methylation is one of the most extensively studied 
epigenetic modifications in eukaryotes consisting of a 
methyl group covalently added to a cytosine, yielding 
5-methylcytosine (5mC).
In addition, robust evidence indicates that the progression 
of NAFLD is associated with both mitochondrial 
dysfunction (6) and genetic diversity in mitochondrial genes 
that encode for members of the oxidative phosphorylation 
(OXPHOS) chain (7). Furthermore, environmental 
factors such alcohol consumption, even in light or 
moderate amounts (8), as well as diet and lifestyle (9), are 
also implicated in the development of a more aggressive 
histological phenotype. Interestingly, available evidence 
indicates that lifestyle factors such as exercise may modify 
epigenetic marks (5).
The histological diagnosis of NASH is based exclusively 
on liver biopsy, which is currently the gold standard 
for determining the disease diagnosis and prognosis 
accurately (10). Unfortunately, this method is not only 
prone to patient complications, but is also expensive, 
while requiring extensive training and advanced skills. In 
the last decade, numerous imaging methods (11) as well 
as circulating molecular biomarkers, including epigenetic 
factors such as miRNAs (12), have been proposed, opened 
up the potential for the non-invasive diagnosis of liver 
fibrosis and advanced NASH. In fact, we have demonstrated 
that circulating miRNAs, in particular miR-122, not only 
mirror histological and molecular events occurring in the 
liver but have a reliable predictive power, allowing simple 
steatosis and NASH to be distinguished (12). In addition, 
we observed that NAFLD has a distinctive circulating 
miRNA profile associated with a global dysmetabolic 
disease-state and cardiovascular risk (12).
The evolving implementation of high-throughput 
OMICs profiling of biological samples—which includes 
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genetic variation, metabolomics,  transcriptomics, 
proteomics, metagenomics and epigenomics—has directly 
influenced the rate of biomarker discovery. Unfortunately, 
integration of this knowledge into the healthcare system 
is time consuming, while also facing other tremendous 
challenges that must be overcome.
Hardy and coworkers have recently published a proof-
of-concept study involving a small sample of patients, which 
findings suggest that plasma DNA methylation signatures 
might reflect the molecular pathology associated with 
fibrotic liver disease (13). Specifically, the authors showed 
that differential DNA methylation at two CpG sites in the 
promoter of peroxisome proliferator-activated receptor γ 
(PPARγ) can be detected within the pool of cell-free DNA 
(cfDNA) of patients with end-stage liver disease, and may 
potentially allow stratifying patients with NAFLD into 
those with mild versus severe fibrosis (13). While interesting 
and promising, these findings deserve some reflections.
The role of epigenetics in the biology of NAFLD
Epigenetic mechanisms play a critical role in the 
reprogramming machinery of hepatocytes and other liver 
cells as a means of adapting to the stressful environment 
caused by the abnormal accumulation of fat and its 
consequences, including inflammation and oxidative 
stress (14). Robust evidence yielded by human studies has 
demonstrated that NAFLD severity is associated with a 
consistent pattern in the methylome and transcriptome 
of the liver tissue characterized by hypermethylation and 
down-regulation of genes involved in metabolic function 
(3,5,15) versus hypomethylation and up-regulation of genes 
involved in liver regeneration, tumorigenesis and tissue 
repair (15). This damage-associated molecular pattern 
is translated into a disease phenotype characterized by 
increased fibrogenesis and metabolic deregulation.
Tissue-specific methylation changes can be 
detected in circulation: the attractive concept of 
liquid biopsy
As mentioned earlier, the distinguishing epigenetic 
modifications associated with NAFLD progression are 
tissue-specific, as they are observed either in the liver of 
the affected patients or other tissues, while still having 
a direct effect on the liver functioning. Whether liver-
related aberrant DNA methylation patterns can be directly 
assessed in the blood by exploring cfDNA, which would 
enable accurate stratification of liver fibrosis associated with 
NASH, remains to be demonstrated in large cohorts.
A remarkable study, as a part of which the researchers 
performed a genome-wide bisulfite sequencing of plasma 
cfDNA, yielded findings indicating that white blood cells 
are the predominant contributors to the circulating DNA 
pool, while cells derived from the liver are sufficiently 
represented as well (16). This finding certainly supports 
the potential for the use of methylation modifications in 
cfDNA as liquid biopsy in the diagnosis and prognosis of 
liver diseases, hepatocellular carcinoma in particular (16). 
Nevertheless, the finding suggesting that two promoter 
CpG sites in PPARγ become hypermethylated as fibrosis 
severity increases, where this observation served as 
a surrogate of specific changes occurring in the liver 
tissue (13), deserves some other considerations. First, 
cfDNA consists of a pool of mixture DNA released from 
different tissues of the body, usually as a byproduct of 
dead—mostly apoptotic—cells. Hence, the question of 
whether NASH-associated significant fibrosis is linked 
to significant hepatocyte cell death that in turn explains 
the source of cfDNA remains unanswered in the study 
conducted by Hardy et al. Unfortunately, the authors did 
not present any morphologic or circulating biomarkers of 
cell death—for instance, caspase-generated cytokeratin-18 
fragments (CK-18)—in association with their findings. 
Extant literature provides some evidence supporting 
the notion that genetic diversity in genes encoding the 
ten-eleven-translocation (TET) family of proteins—
which are responsible for catalyzing the conversion of 
5-methylcytosine to 5-hmC—is involved in the epigenetic 
regulation of programmed liver-cell death in patients with 
NASH (4). Thus, the connection between advanced fibrosis 
and epigenetic modifications that eventually feed the pool of 
cfDNA in patients with NASH is still not fully elucidated.
Second, the selection of PPARγ as the candidate gene 
for exploring surrogate liver DNA methylation changes in 
the blood represents a significant challenge due to the high 
expression levels of this gene in many different tissues that 
are strongly associated with the biology of NAFLD and 
related co-morbidities. For example, under physiological 
conditions, PPARγ exhibits the highest expression in adipose 
tissue, and is lower in skeletal muscle, spleen, heart and the 
liver; however, PPARγ is also detectable in placenta, lung 
and ovary. A comprehensive list of tissues in which PPARγ 
is expressed, as well as the magnitude of its expression, is 
shown in Table 1. Interestingly, in disease states, including 
the metabolic syndrome and obesity—two conditions 
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strongly associated with advanced fibrosis in NASH—
PPARγ is hypermethylated in adipocytes (17). Furthermore, 
recent evidence indicates that transient PPARγ promoter 
methylation occurs after common events of ordinary life, 
for instance, physical exercise or caffeine consumption (18). 
Hence, dynamic changes associated with epigenetic 
modifications may specifically jeopardize the selection of 
PPARγ as the “candidate gene” for use as a biomarker of 
liver fibrosis.
Challenges: translating laboratory work into the 
clinical practice
The presence of cfDNA in the circulating compartment 
was demonstrated three decades ago (19), leading to 
the emergence of liquid biopsy. The applications of this 
innovative concept in the clinical setting are summarized 
in Table 2. However, the implementation of cfDNA 
methylation as a non-invasive molecular tool for the 
Table 1 Gene expression analysis of human PPARγ (ENSG00000132170) in physiological conditions
Tissue Rank score# Source Developmental stage(s)
Adipose tissue 2.17e3 Affymetrix, EST, RNA-Seq 5 stages
Subcutaneous adipose tissue 2.64e3 Affymetrix 3 stages
Blood 3.09e4 Affymetrix 5 stages
sigmoid colon 4.85e3 Affymetrix 3 stages
Layer of synovial tissue 4.72e3 Affymetrix 7 stages
Colon 5.37e3 Affymetrix, EST, RNA-Seq 7 stages
Prostate gland 5.38e3 Affymetrix, EST, RNA-Seq 3 stages
Heart 6.05e3 Affymetrix, EST, RNA-Seq 4 stages
Lymph node 6.23e3 RNA-Seq 1 stage
Adrenal gland 6.42e3 Affymetrix, RNA-Seq 2 stages
Thyroid gland 7.59e3 Affymetrix, RNA-Seq 4 stages
Mucosa of sigmoid colon 7.77e3 Affymetrix 1 stage
Omental fat pad 7.84e3 Affymetrix 1 stage
Liver 7.87e3 Affymetrix, RNA-Seq 5 stages*
Mammalian vulva 8.45e3 Affymetrix 1 stage
Female gonad 8.99e3 Affymetrix, EST, RNA-Seq 9 stages
Jejunal mucosa 9.61e3 Affymetrix 1 stage
Skeletal muscle tissue 1.10e4 RNA-Seq 1 stage
Duodenum 1.23e4 Affymetrix 1 stage
Coronary artery 1.27e4 Affymetrix 1 stage
Data was retrieved from the Bgee database, available at http://bgee.org/ that compares gene expression patterns from multiple data 
types (RNA-Seq, Affymetrix, in situ hybridization, and EST data) in different developmental stages. The Bgee database consists of curate 
normal-healthy expression (e.g., no gene knock-out, no treatment, no disease), to provide a comparable reference of normal gene 
expression data. #, rank scores: rank scores of expression calls are normalized across genes, conditions and species; *, developmental 
stage(s) for liver tissue: HsapDv:0000090, 25 to 44-year-old human stage (human); HsapDv:0000092, human middle-aged stage (human); 
HsapDv:0000089, young adult stage (human); HsapDv:0000197, third LMP month human stage (human); UBERON:0000104, life cycle. 
Sources of raw data: Affymetrix data, ArrayExpress; EST data, UniGene; RNA-Seq data, GEO. PPARγ, peroxisome proliferator-activated 
receptor γ.
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diagnosis of fibrosis imposes tremendous analytical 
and technical challenges because cfDNA is not only 
highly fragmented (~170–500 bp) but also circulates at 
very low concentrations (1.8–44 ng/mL). The fact that 
exploration of DNA methylation signatures requires a 
previous step of DNA bisulfitation or other complex and 
protracted techniques, such as 5mC-containing DNA 
immunoprecipitation and sequencing, imposes further 
obstacles to the adoption of this method. The three main 
pitfalls to overcome before cfDNA methylation could be 
employed as biomarker of fibrosis are illustrated in Figure 1. 
Available evidence suggests that a considerable gap between 
innovation and implementation still exists, preventing 
definitive affirmation that plasma DNA methylation 
signatures reflect the molecular pathology associated with 
fibrotic liver disease. Nonetheless, this is a promising 
horizon toward which further research efforts should be 
directed.
Figure 1 Obstacles to translating the concept of cell free DNA (cfDNA) methylation into the clinical setting for the stratification of liver 
fibrosis. This image illustrates the three main pitfalls that must be overcome before cfDNA methylation could be employed as a fibrosis 
biomarker, namely: (I) the ultimate source of cfDNA should be clearly demonstrated, as cfDNA circulates as a pool of DNA originating 
from dead cells from the entire body, particularly blood cells; (II) cfDNA is highly fragmented (~170–500 bp) and circulates at very low 
levels; and (III) exploration of aberrant patterns of DNA methylation in cfDNA requires large amounts of DNA to guarantee proper bisulfite 
conversion of DNA.
Table 2 Liquid biopsy of circulating nucleotide acids in the clinical 
setting
Detection of tumor mutations in circulating tumor DNA
Molecular cytogenetic analysis
DNA methylation of genes mutated in tumors
Genetic alterations in tumors: microsatellite instability and loss 
of heterozygosity
Detection of fetal genomic abnormalities
Tissue-specific methylation changes 
may be detected in circulation
Challenges: wide-spread clinical implementation?
cfDNA is at very low concentrations
Isolation and quantitation
Highly fragmented DNA
Aberrant DNA 
methylation changes
Cell free DNA
Liver tissue
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